SLS SELLAS Life Sciences Group Inc

Price (delayed)

$11.52

Market cap

$2.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$2.19B

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial ...

Highlights
SLS's EPS is up by 34% year-on-year and by 9% since the previous quarter
SELLAS Life Sciences Group's equity has increased by 28% from the previous quarter
SELLAS Life Sciences Group's net income has decreased by 24% YoY and by 10% QoQ

Key stats

What are the main financial stats of SLS

SLS stock price

How has the SELLAS Life Sciences Group stock price performed over time
Intraday
-4.16%
1 week
-1.2%
1 month
-25.49%
1 year
577.65%
YTD
205.57%
QTD
-21.95%

Financial performance

How have SELLAS Life Sciences Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.22M
Net income
-$32.46M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 30% YoY and by 12% from the previous quarter
SELLAS Life Sciences Group's net income has decreased by 24% YoY and by 10% QoQ

Price vs fundamentals

How does SLS's price correlate with its fundamentals

Growth

What is SELLAS Life Sciences Group's growth rate over time

Valuation

What is SELLAS Life Sciences Group stock price valuation
P/E
N/A
P/B
15.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SLS's EPS is up by 34% year-on-year and by 9% since the previous quarter
SLS's price to book (P/B) is 87% higher than its 5-year quarterly average of 8.7 and 69% higher than its last 4 quarters average of 9.6
SELLAS Life Sciences Group's equity has increased by 28% from the previous quarter

Efficiency

How efficient is SELLAS Life Sciences Group business performance
The company's return on equity has surged by 73% YoY and by 24% QoQ
SELLAS Life Sciences Group's return on assets has surged by 64% YoY and by 22% QoQ

Dividends

What is SLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLS.

Financial health

How did SELLAS Life Sciences Group financials performed over time
The total assets is up by 27% since the previous quarter
SLS's total liabilities is up by 26% YoY and by 14% QoQ
SELLAS Life Sciences Group's debt is 99% lower than its equity
The debt to equity has plunged by 67% YoY
SELLAS Life Sciences Group's equity has increased by 28% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.